Croma-Pharma Expands Successful Mask Range With Face Masks for Different Areas of Application
21.10.2021 12:38:00 EEST | Business Wire | Press release
Croma-Pharma (Croma) announced today the expansion of its successful mask portfolio. The carefully selected ingredients of each formulation, as well as the sheet material, are tailored to specific application areas and skin needs. The products have a pleasant texture and are suitable for all skin types.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021005468/en/
@Croma (Photo: Business Wire)
The right mask for every need
The Croma mask portfolio offers two full face masks, as well as masks for specific areas of the face including the eyes, lips, and laugh lines.
Calming face mask with aloe vera, green tea and rosehip oil
The Croma calming face mask contains ingredients known for their antioxidant and soothing effects, as well as skin-regenerating properties. It replenishes the skin with vitamins and helps to protect against harmful environmental influences. Regular use may help to strengthen the skin barrier and provides optimal care for the skin. The material consists of 80 percent green tea fibers and 20 percent cupro - so not only the serum per se works to achieve the desired effect, but also the mask material itself.
Key ingredients: hyaluronic acid, rosehip oil, green tea leaf extract, aloe vera juice
Recommended retail price: EUR 59,-
Rejuvenating face mask with hyaluronic acid
This hyaluronic acid mask has long been considered to be one of Croma Pharma Skincare's most popular products. The incorporated ingredients refresh dehydrated skin, alleviate visible dryness and help to improve the skin’s elasticity. In addition to its pleasant cooling effect, the formulation may help to smooth small wrinkles and ensures a radiant complexion. Regular use can help to fight the signs of skin aging and maintain a youthful appearance.
Key ingredients: hyaluronic acid, imperata cylindrica root extract, irish moss extract
Recommended retail price: EUR 59,-
Organic cellulose masks for special facial areas
Energizing eye mask with hyaluronic acid, kiwi and cucumber extract
Croma energizing eye mask provides an instant boost of hydration. The mask is packed with soothing ingredients which sustainably improve the skin barrier function and skin elasticity. The fermented extracts nourish the skin with valuable postbiotics. The eye mask contains powerful antioxidants – including vitamin C – and helps to moisturize and reduce signs of fatigue, while providing an extra energy kick for a fresh and energized appearance.
Key ingredients: hyaluronic acid, kiwi fruit ferment, cucumber extract
Recommended retail price: EUR 55,-
Regenerating lip mask with hyaluronic acid, aloe vera and berry ferment
The regenerating lip mask infused with hyaluronic acid, aloe vera and berry ferment that deeply moisturize the delicate lip area while providing a cooling and regenerating effect. The ingredients soften and plump the lips.
Key ingredients: hyaluronic acid, aloe vera, berry ferment
Recommended retail price: EUR 55,-
Firming laugh line mask with hyaluronic acid and pomegranate extract
Croma firming mask for laugh lines is enriched with hyaluronic acid to intensely hydrate and soothe the skin of the nasolabial folds. The carefully selected ingredients include Palmitoyl hexapeptide, a biomimetic peptide that gives a firming effect and can smooth the appearance of wrinkles. Pomegranate ferment extract, a potent antioxidant, may increase skin collagen.
Key ingredients: hyaluronic acid, palmitoyl hexapeptide-12, pomegranate fermented extract
Recommended retail price: EUR 55,-
Croma expert tip - the right application
Croma Expert Tip by Dr. Monika Sulovsky, Yuvell® Committed to Beauty: “A moisturizing mask is a freshness boost for any skin type and can easily be applied in the morning or evening.
- Step 1: A face mask is always applied to a cleansed face and is used before serums or creams.
- Step 2: The mask should be left on for 15 minutes.
- Step 3: Finally, remove the mask and gently massage the excess serum into the skin.”
“Our Croma face masks have been very popular for a long time. This was also a welcome occasion for us to expand the portfolio in order to be able to offer our customers a comprehensive beauty treatment at home", explains Andreas Prinz, the Managing Director of Croma-Pharma.
Availability
The Croma masks are available via www.cromaskincareshop.com and selected partners.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses its own branded products on minimally invasive aesthetic medicine. In addition to a broad range of HA fillers produced on site, Croma also markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high-quality skincare technologies in its core strategic markets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005468/en/
Contact information
CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Cromazeile 2
A-2100 Leobendorf
Tel.: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at
CROMA-PHARMA GmbH
Simone Turek
External Communications Manager
Cromazeile 2
A-2100 Leobendorf
Tel.: +43 676 846868 654
Mail: simone.turek@croma.at
Web: www.croma.at
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 15:00:00 EET | Press release
Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end workflows spanning onboarding, KYC, AML, fraud, underwriting, payments, disputes, servicing, and collections. For
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom